62
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The first cancer-targeted microRNA (miRNA) drug - MRX34, a liposome-based miR-34 mimic - entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in April 2013, and miRNA therapeutics are attracting special attention from both academia and biotechnology companies. Although miRNAs are the most studied non-coding RNAs (ncRNAs) to date, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. Here, we summarize the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges.

          Related collections

          Author and article information

          Journal
          Nat Rev Drug Discov
          Nature reviews. Drug discovery
          Springer Science and Business Media LLC
          1474-1784
          1474-1776
          Nov 2013
          : 12
          : 11
          Affiliations
          [1 ] 1] Experimental Therapeutics and Leukemia Department, MD Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA. [2].
          Article
          nrd4140 NIHMS716394
          10.1038/nrd4140
          4548803
          24172333
          4d8216c0-e10a-4a0c-990d-5acb959ce81f
          History

          Comments

          Comment on this article